• No results found

[PDF] Top 20 Venlafaxine extended release (XR) in the treatment of panic disorder

Has 10000 "Venlafaxine extended release (XR) in the treatment of panic disorder" found on our website. Below are the top 20 most common "Venlafaxine extended release (XR) in the treatment of panic disorder".

Venlafaxine extended release (XR) in the treatment of panic disorder

Venlafaxine extended release (XR) in the treatment of panic disorder

... Venlafaxine XR, a structurally novel phenylethylamine antidepressant, has a dual mechanism of action, acting as both a serotonin and norepinephrine reuptake inhibitor (SNRI), with little or no affinity for ... See full document

12

Venlafaxine in the treatment of panic disorder

Venlafaxine in the treatment of panic disorder

... symptom panic attacks in the 17 days preceding entry into the study) were randomly enrolled in the 10-week trial of venlafaxine or ...symptom panic attacks (≥4 symptoms) as measured on the PAAS ... See full document

10

Xenon in the treatment of panic disorder: an open label study

Xenon in the treatment of panic disorder: an open label study

... the treatment of PD, especially given the importance of achievement of rapid anxiolytic effect [10, ...the treatment of refractory PD, where both first- and second-line treat- ment options are ...where ... See full document

10

A controlled trial of quetiapine XR coadministration treatment of SSRI-resistant panic disorder

A controlled trial of quetiapine XR coadministration treatment of SSRI-resistant panic disorder

... and identical-appearing PLAC tablets provided by Astra Zeneca (50, 200, and 300 mg designations). The extend release (XR) preparation of quetiapine was chosen for its potential to limit common side-effects ... See full document

7

Panic disorder: from psychopathology to treatment

Panic disorder: from psychopathology to treatment

... background, depression and alcohol or benzodiazepine abuse (BDZ), usually used as self therapy against panic attacks. Most of the time, all these phenomenological events appear after the onset of panic ... See full document

10

COMPARISON OF EFFICACY OF EXTENDED RELEASE VENLAFAXINE VERSUS SERTRALINE IN TREATMENT OF PATIENTS WITH MAJOR DEPRESSIVE DISORDER

COMPARISON OF EFFICACY OF EXTENDED RELEASE VENLAFAXINE VERSUS SERTRALINE IN TREATMENT OF PATIENTS WITH MAJOR DEPRESSIVE DISORDER

... to treatment and only twenty percent would have complete recovery of symptoms; among them 60 percent were under treatment with antidepressants [7] .... Venlafaxine is another antidepressant from ... See full document

7

Update on extended release quetiapine fumarate in schizophrenia and bipolar disorders

Update on extended release quetiapine fumarate in schizophrenia and bipolar disorders

... immediate release (IR) and as an extended release (XR) formulation allowing flexibility of dosing for indi- vidual ...quetiapine XR include the treatment of schizophrenia ... See full document

14

A randomized, double-blind study of the efficacy and tolerability of extended-release quetiapine fumarate (quetiapine XR) monotherapy in patients with major depressive disorder

A randomized, double-blind study of the efficacy and tolerability of extended-release quetiapine fumarate (quetiapine XR) monotherapy in patients with major depressive disorder

... quetiapine XR 150 versus 300 mg/day, as it mimicked medication titration used in clinical practice when a patient does not respond to the initial treatment ... See full document

16

FORMULATION DEVELOPMENT OF VENLAFAXINE HYDROCHLORIDE EXTENDED RELEASE PELLETS BY EXTRUSION SPHERONIZATION METHOD

FORMULATION DEVELOPMENT OF VENLAFAXINE HYDROCHLORIDE EXTENDED RELEASE PELLETS BY EXTRUSION SPHERONIZATION METHOD

... prepare extended release pellets of Venlafaxine ...work, extended release pellets of Venlafaxine was prepared by extrusion spheronization method using combination of hydrophobic ... See full document

8

An open label trial of divalproex sodium extended release for pediatric bipolar spectrum disorder in children age 6   12 years

An open label trial of divalproex sodium extended release for pediatric bipolar spectrum disorder in children age 6 12 years

... this treatment or if the subject’s parent did not wish to stop stimulant treatment and only if the patient had been on a stable dose for at least 30 ...(Adderall XR 20 mg/day) was maintained ... See full document

6

A cost-utility analysis of pregabalin versus venlafaxine XR in the treatment of generalized anxiety disorder in Portugal

A cost-utility analysis of pregabalin versus venlafaxine XR in the treatment of generalized anxiety disorder in Portugal

... The analysis presented on Table 6 shows that results are robust, i.e., are not influenced by the hypotheses assumed. Only if the time horizon was set to 8 weeks, there would be an important increase on the incremental ... See full document

8

Factors impacting the efficacy of venlafaxine extended release 75–225 mg/day in patients with major depressive disorder: exploratory post hoc subgroup analyses of a randomized, double-blind, placebo-controlled study in Japan

Factors impacting the efficacy of venlafaxine extended release 75–225 mg/day in patients with major depressive disorder: exploratory post hoc subgroup analyses of a randomized, double-blind, placebo-controlled study in Japan

... favorable treatment effect compared with placebo in most subgroups, the flexible-dose group showed a relatively smaller treatment effect than the fixed-dose group in most ...greater treatment effect ... See full document

12

A STUDY ON BIOPOLYMERIC NANOPARTICLES AS AN EFFECTIVE CARRIER FOR ANTIDEPRESSANT DRUG DELIVERY SYSTEM

A STUDY ON BIOPOLYMERIC NANOPARTICLES AS AN EFFECTIVE CARRIER FOR ANTIDEPRESSANT DRUG DELIVERY SYSTEM

... After reacting with alginate the peaks of chitosan (both commercial and isolated) too seems to have a characteristic shift 3396.76cm -1 (the amine and hydroxyl groups), 2360.95cm -1 (phenyl ring substitutions) and ... See full document

9

Assessment of efficacy and tolerability of once-daily extended release metformin in patients with type 2 diabetes mellitus

Assessment of efficacy and tolerability of once-daily extended release metformin in patients with type 2 diabetes mellitus

... Switchover to metformin XR had no effect on hs C- reactive protein, a biomarker of chronic inflammatory disease. Previous studies have shown mixed results of metformin therapy on C-reactive protein and overall, ... See full document

6

Panic disorder and incident coronary heart disease: a systematic review and meta-analysis protocol

Panic disorder and incident coronary heart disease: a systematic review and meta-analysis protocol

... self-reported panic attack ...of panic disorder studies with varying levels of validity and ...that panic precedes CHD, when it is plausible that panic is merely a manifestation of un- ... See full document

8

Clinical use of extended-release oral treprostinil in the treatment of pulmonary arterial hypertension

Clinical use of extended-release oral treprostinil in the treatment of pulmonary arterial hypertension

... their pivotal findings demonstrating that intravenous (IV) epoprostenol improved 6-minute walk distance (6MWD) and hemodynamics. Though the patient numbers were small and the study duration was short, this remains the ... See full document

7

 PHARMACOKINETIC AND BIOEQUIVALENCE COMPARISON BETWEEN EXTENDED RELEASE CAPSULES OF VENLAFAXINE HYDROCHLORIDE 150MG: AN OPEN LABEL, BALANCED, RANDOMIZED-SEQUENCE, SINGLE-DOSE, TWO-PERIOD CROSSOVER STUDY IN HEALTHY INDIAN MALE VOLUNTEERS

 PHARMACOKINETIC AND BIOEQUIVALENCE COMPARISON BETWEEN EXTENDED RELEASE CAPSULES OF VENLAFAXINE HYDROCHLORIDE 150MG: AN OPEN LABEL, BALANCED, RANDOMIZED-SEQUENCE, SINGLE-DOSE, TWO-PERIOD CROSSOVER STUDY IN HEALTHY INDIAN MALE VOLUNTEERS

... of venlafaxine hydrochloride of the test or reference product was administered 30 minutes after starting a high fat, high calorie breakfast at the same time in the morning before ...next treatment following ... See full document

8

Quality by Design (Qbd) Assisted Development of Extended Release Pellets of Venlafaxine HCL

Quality by Design (Qbd) Assisted Development of Extended Release Pellets of Venlafaxine HCL

... Pellets prepared using 47% of L-HPC LH-31 (spheronizing agent) and 3% of Hypromellose 15 cps binder solution using extruder fitted with 1.0 mm die roller and spheronizer with 3.25 mm chequered plate. Final weight of ... See full document

9

 MENTAL HEALTH CHALLENGES AND POSSIBLE SOLUTIONS WITH SPECIAL REFERENCE TO ANXIETY

 MENTAL HEALTH CHALLENGES AND POSSIBLE SOLUTIONS WITH SPECIAL REFERENCE TO ANXIETY

... Herbal remedies for anxiety are used as alternative treatment for anxiety disorder. Though an herbal remedy for anxiety has been known to man for a long time, advances in medicine and the resulting ... See full document

6

Clinical utility of guanfacine extended release in the treatment of ADHD in children and adolescents

Clinical utility of guanfacine extended release in the treatment of ADHD in children and adolescents

... Guanfacine XR is a safe and well-tolerated therapeutic option for the treatment of ADHD (Table ...guanfacine XR does not have an abuse potential and has the benefit to be combined with other ... See full document

9

Show all 10000 documents...